MedPath

NMPA Approvals

Chinese National Medical Products Administration approved drug approval numbers and registration information

National Medical Products Administration
China
166,322 Approvals
Showing 2101 to 2120 of 166,322 approvalsPage 106 of 8317

Lidocaine and Prilocaine Cream

Approval Number: 国药准字H20249822
Registration: Dec 25, 2024

Olmesartan Medoxomil and Amlodipine Besylate Tablets

Approval Number: 国药准字H20249787
Registration: Dec 25, 2024

Fexofenadine Hydrochloride Oral Suspension

Approval Number: 国药准字H20249766
Registration: Dec 25, 2024

Tadalafil Tablets

Approval Number: 国药准字H20249849
Registration: Dec 25, 2024

Roxadustat Capsules

Approval Number: 国药准字H20249771
Registration: Dec 25, 2024

Pregabalin Oral Solution

Approval Number: 国药准字H20249839
Registration: Dec 25, 2024

Tacrolimus Capsules

Approval Number: 国药准字HJ20240166
Registration: Dec 25, 2024

Linagliptin Tablets

Approval Number: 国药准字H20249802
Registration: Dec 25, 2024

Atenolol Tablets

Approval Number: 国药准字H20249783
Registration: Dec 25, 2024

Fluoxetine Hydrochloride Oral Solution

Approval Number: 国药准字H20249832
Registration: Dec 25, 2024

Phloroglucinol Injection

Approval Number: 国药准字H20249798
Registration: Dec 25, 2024

Ropivacaine Hydrochloride Injection

Approval Number: 国药准字H20249833
Registration: Dec 25, 2024

Azithromycin for Suspension

Approval Number: 国药准字H20249812
Registration: Dec 25, 2024

Lornoxicam for Injection

Approval Number: 国药准字H20249829
Registration: Dec 25, 2024

小儿清解颗粒

Approval Number: 国药准字Z11020688
Registration: Dec 25, 2024

Phenylephrine Hydrochloride Injection

Approval Number: 国药准字H20249841
Registration: Dec 25, 2024

Tagitanlimab Injection

Approval Number: 国药准字S20240058
Registration: Dec 25, 2024

Lenacapavir Sodium Injection

Approval Number: 国药准字HJ20240170
Registration: Dec 25, 2024

Tadalafil Tablets

Approval Number: 国药准字H20249799
Registration: Dec 25, 2024

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.